BioCardia, Inc. Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
BioCardia, Inc. (BCDA) reported Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$3.00 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2020-05-15
- BioCardia, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was -$3.00M.
- BioCardia, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was -$2.52M.
- BioCardia, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-03-31 was -$3.04M.
- BioCardia, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2017-03-31 was -$2.32M.
- BioCardia, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $227.00K.
- BioCardia, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was -$7.33M.
- BioCardia, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2017 was -$8.66M, a 148.68% decline from fiscal 2016.
- BioCardia, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2016 was $17.80M, a 4670.78% increase from fiscal 2015.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$3.00M 10-Q · filed 2020-05-15 | |||
| 2019-12-31 | $227.00K 10-K · filed 2020-04-09 | |||
| 2019-09-30 | $3.55M 10-Q · filed 2019-11-19 | |||
| 2019-06-30 | -$4.84M 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | -$2.52M 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | -$7.33M 10-K · filed 2020-04-09 | |||
| 2018-09-30 | -$7.87M 10-Q · filed 2019-11-19 | |||
| 2018-06-30 | -$5.86M 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | -$3.04M 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | -$8.66M 10-K · filed 2020-04-09 | |||
| 2017-09-30 | -$8.03M 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | -$6.24M 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | -$2.32M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $17.80M 10-K · filed 2019-04-02 | |||
| 2016-09-30 | -$3.00M 10-Q · filed 2017-11-09 | |||
| 2016-06-30 | -$1.87M 10-Q · filed 2017-08-14 | |||
| 2016-03-31 | -$748.00K 10-Q · filed 2017-05-11 | |||
| 2015-12-31 | $373.00K 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |